Marker Therapeutics Files 8-K
Ticker: MRKR · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, financials, filing-update
Related Tickers: MRKR
TL;DR
Marker Therapeutics (MRKR) filed an 8-K on 4/8. Standard update.
AI Summary
Marker Therapeutics, Inc. filed an 8-K on April 8, 2024, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides an update on the company's corporate events and financial status, which is crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate events and financial statements, not indicating any immediate significant risk.
Key Numbers
- 001-37939 — SEC File Number (Identifier for the filing)
- 45-4497941 — IRS Employer Identification No. (Company tax identifier)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former company name
- GENEMAX CORP (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
- April 8, 2024 (date) — Date of report
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items of disclosure, but the specific details of the 'Other Events' are not provided in the header information.
When was Marker Therapeutics, Inc. previously known as TAPIMMUNE INC.?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. with a date of name change on June 29, 2017.
What is the principal executive office address for Marker Therapeutics, Inc.?
The principal executive offices are located at 9350 Kirby Drive, Suite 300, Houston, Texas, 77054.
What is the Standard Industrial Classification (SIC) code for Marker Therapeutics, Inc.?
The Standard Industrial Classification code for Marker Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Marker Therapeutics, Inc.?
The fiscal year end for Marker Therapeutics, Inc. is December 31 (1231).
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-08 07:09:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2411143d1_8k.htm (8-K) — 23KB
- tm2411143d1_ex99-1.htm (EX-99.1) — 18KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001104659-24-044496.txt ( ) — 223KB
- mrkr-20240408.xsd (EX-101.SCH) — 3KB
- mrkr-20240408_lab.xml (EX-101.LAB) — 33KB
- mrkr-20240408_pre.xml (EX-101.PRE) — 22KB
- tm2411143d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On April 8, 2024, the Company issued a press release announcing that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024 and reported that study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: April 8, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer